Who is sponsoring NCT05661318?

NCT05661318 is sponsored by Magdi Yacoub Heart Foundation.

What drugs are being tested in NCT05661318?

Interventions in NCT05661318: Risk assessment.

What condition does NCT05661318 study?

NCT05661318 studies Genetic Predisposition to Disease.

Is NCT05661318 still recruiting?

NCT05661318 is currently recruiting now. Last updated 29 May 2024.

Last reviewed 2024-05-29 · How we verify

NCT05661318: AHC-BHS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AHC Ballana Heart Study

Recruiting now Last updated 29 May 2024

What this trial tests

trial testing Risk assessment in Genetic Predisposition to Disease in 5,000 participants. Currently enrolling.

Timeline

1 January 2018

Primary endpoint
31 December 2050

31 January 2055

Quick facts

Lead sponsor	Magdi Yacoub Heart Foundation
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	5,000
Start date	1 January 2018
Primary completion	31 December 2050
Estimated completion	31 January 2055
Sites	1 location across Egypt

Drugs / interventions tested

Risk assessment

Conditions studied

Genetic Predisposition to Disease — all drugs for Genetic Predisposition to Disease →

Sponsor

Magdi Yacoub Heart Foundation

Who can join

18 and older, any sex, with Genetic Predisposition to Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Study is designed to assess CVD incidence, prevalence, progression and related risk factors, including genetic background. It will provide an important base for all cardiovascular research activities in our centre and help in designing future studies and guide policy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Genetic Predisposition to Disease

Currently open trials in the same condition.

NCT06962059 — Healthy Volunteers Study · recruiting
NCT07018128 — Expression of Genes Relating Hypertension and Efficacy of 4-7-8 Breathing Control on Reducing Blood Pressure · NA · recruiting
NCT06399666 — Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation · recruiting
NCT05772559 — Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, · recruiting
NCT05759143 — Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing · NA · recruiting

Other Magdi Yacoub Heart Foundation trials

Trials by the same sponsor.

NCT05661305 — Aswan Heart Centre - Egyptian Healthy Volunteers · recruiting
NCT05884892 — Egyptian Hypertrophic Cardiomyopathy Program · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05661318 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Magdi Yacoub Heart Foundation
Last refreshed: 29 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05661318.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing